Saptalis Pharmaceuticals
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
45 Davids Dr, Hauppauge, New York, 11788...Phone Number
(631) 231-2751Website
www.saptalis.comRevenue
$9.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Saptalis Pharmaceuticals
Saptalis Pharmaceuticals is a pharmaceutical company that specializes in the development and manufacturing of innovative medications. The company focuses on providing high-quality healthcare solutions to improve patient outcomes. Their intended clients include healthcare providers, hospitals, and patients seeking effective treatments. Saptalis is committed to advancing medical science through research and development.Explore more
Saptalis Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Saptalis Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Saptalis Pharmaceuticals
Earning: See what the market has to say on Saptalis Pharmaceuticals recently announced quarterly report
Check if Saptalis Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Saptalis Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Saptalis Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Saptalis Pharmaceuticals launches new products
Check out if Saptalis Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Saptalis Pharmaceuticals has new funding data
Recommended Actions
Reach out to Masked Content who joined Saptalis Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Saptalis Pharmaceuticals
Compare insights from companies similar to Saptalis Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Saptalis Pharmaceuticals
$9.1M
11-50
Private
$6.8M
2015
PS
Peruvemba SatishChief Financial Officer & Chief Commercial Officer ( Cco)
Company Profile Activity
Activity Insights
Saptalis Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Saptalis Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Saptalis Pharmaceuticals.
Saptalis Pharmaceuticals financials insights
Gather financial insights about Saptalis Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$6.5M
2020
Debt
$350K
Saptalis Pharmaceuticals Tech Stack
A closer look at the technologies used by Saptalis Pharmaceuticals
Saptalis Pharmaceuticals News & Media
Saptalis Pharmaceuticals Launches Fluoxetine Oral Solution, USP 20 mg/5 mL
HAUPPAUGE, N.Y.--(BUSINESS WIRE)-- #Depression--Saptalis Pharmaceuticals, LLC. is pleased to announce the commercial launch of Fluoxetine Oral Solution, USP 20 mg/5 mL, a prescription-only selective serotonin reuptake inhibitor (SSRI) developed to treat a range of mental health conditions effectively. This oral formulation is designed to support flexible and individualized treatment, particularly for patients who experience difficulty swallowing solid dosage forms. Fluoxetine Oral Solution is inAppili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZKesin Pharma Announces FDA Approval and U.S. Availability of LIKMEZ™ (metronidazole) Oral Suspension
OLDSMAR, Fla.--(BUSINESS WIRE)--Kesin Pharma Corporation, a pharmaceutical company focused on innovative Specialty brands and Unit Dose formulations, announced today that the U.S. Food and Drug Administration (FDA) has approved LIKMEZ™ (metronidazole) oral suspension, 500 mg/5 mL. Available now, LIKMEZ™ is the first and only FDA-approved ready-to-use oral liquid metronidazole in the U.S. market. LIKMEZ™ is a novel presentation of a mainstay antibiotic drug, reinvented to address common adherencAppili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from the U.S. Food and Drug Administration ("FDA”) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501). ATI-1501, Appili’s liquid oral reformulation of
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Saptalis Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Saptalis Pharmaceuticals is a pharmaceutical company that specializes in the development and manufacturing of innovative medications. The company focuses on providing high-quality healthcare solutions to improve patient outcomes. Their intended clients include healthcare providers, hospitals, and patients seeking effective treatments. Saptalis is c... Read More
